SAFETY AND EFFICACY OF SUBCUTANEOUS TOCILIZUMAB IN ADULTS WITH SYSTEMIC SCLEROSIS: WEEK 24 DATA FROM A PHASE II/II TRIAL

被引：0
|
作者：
Denton, Christopher P. [1 ]
Khanna, Dinesh [2 ]
van Laar, Jaap M. [3 ]
Jahreis, Angelika [4 ]
Cheng, Sabrina [4 ]
Spotswood, Helen [5 ]
Siegel, Jeffrey [4 ]
Furst, Daniel E. [6 ]
机构：
[1] UCL, Sch Med, Dept Rheumatol, London W1N 8AA, England
[2] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA
[3] Univ Med Ctr Utrecht, Dept Rheumatol, Utrecht, Netherlands
[4] Genentech Inc, Dept Med, San Francisco, CA 94080 USA
[5] Roche Prod Ltd, Dept Med, Welwyn Garden City AL7 3AY, Herts, England
[6] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA
来源：
RHEUMATOLOGY | 2015年 / 54卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
O17
引用
收藏
页码：32 / 32
页数：1
相关论文
共 50 条
  • [1] SUBCUTANEOUS TOCILIZUMAB IN ADULTS WITH SYSTEMIC SCLEROSIS: 24 AND 48 WEEK SAFETY AND EFFICACY DATA FROM THE FASSCINATE TRIAL
    Denton, Christopher
    Khanna, Dinesh
    Jahreis, Angelika
    van Laar, Jacob M.
    Cheng, Sabrina
    Spotswood, Helen
    Pope, Janet E.
    Allanore, Yannick
    Mueller-Ladner, Ulf
    Siegel, Jeffrey
    Furst, Daniel E.
    [J]. RHEUMATOLOGY, 2016, 55 : 47 - 48
  • [2] Safety and Efficacy of Subcutaneous Tocilizumab in Adults with Systemic Sclerosis: Week 24 Data from a Phase 2/3 Trial.
    Khanna, Dinesh
    Denton, Christopher P.
    van Laar, Jacob M.
    Jahreis, Angelika
    Cheng, Sabrina
    Spotswood, Helen
    Siegel, Jeffrey
    Furst, Daniel E.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S386 - S386
  • [3] SAFETY AND EFFICACY OF SUBCUTANEOUS TOCILIZUMAB IN ADULTS WITH SYSTEMIC SCLEROSIS: WEEK 48 DATA FROM THE FASSCINATE TRIAL
    Khanna, D.
    Denton, C. P.
    Jahreis, A.
    van Laar, J. M.
    Cheng, S.
    Spotswood, H.
    Pope, J. E.
    Allanore, Y.
    Mueller-Ladner, U.
    Siegel, J.
    Furst, D. E.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 87 - 88
  • [4] Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial
    Khanna, Dinesh
    Denton, Christopher P.
    Jahreis, Angelika
    van Laar, Jacob M.
    Frech, Tracy M.
    Anderson, Marina E.
    Baron, Murray
    Chung, Lorinda
    Fierlbeck, Gerhard
    Lakshminarayanan, Santhanam
    Allanore, Yannick
    Pope, Janet E.
    Riemekasten, Gabriela
    Steen, Virginia
    Mueller-Ladner, Ulf
    Lafyatis, Robert
    Stifano, Giuseppina
    Spotswood, Helen
    Chen-Harris, Haiyin
    Dziadek, Sebastian
    Morimoto, Alyssa
    Sornasse, Thierry
    Siegel, Jeffrey
    Furst, Daniel E.
    [J]. LANCET, 2016, 387 (10038): : 2630 - 2640
  • [5] Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)
    Khanna, Dinesh
    Denton, Christopher P.
    Lin, Celia J. F.
    van Laar, Jacob M.
    Frech, Tracy M.
    Anderson, Marina E.
    Baron, Murray
    Chung, Lorinda
    Fierlbeck, Gerhard
    Lakshminarayanan, Santhanam
    Allanore, Yannick
    Pope, Janet E.
    Riemekasten, Gabriela
    Steen, Virginia
    Mueller-Ladner, Ulf
    Spotswood, Helen
    Burke, Laura
    Siegel, Jeffrey
    Jahreis, Angelika
    Furst, Daniel E.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (02) : 212 - 220
  • [6] Safety and Efficacy of Subcutaneous Tocilizumab in Systemic Sclerosis: Results from the Open-Label Period of a Phase 3 Trial
    Khanna, Dinesh
    Lin, Celia J. F.
    Spotswood, Helen
    Siegel, Jeffrey
    Furst, Daniel
    Denton, Christopher
    [J]. ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [7] Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis
    Spiera, Robert
    Hummers, Laura
    Chung, Lorinda
    Frech, Tracy M.
    Domsic, Robyn
    Hsu, Vivien
    Furst, Daniel E.
    Gordon, Jessica
    Mayes, Maureen
    Simms, Robert
    Lafyatis, Robert
    Martyanov, Viktor
    Wood, Tammara
    Whitfield, Michael L.
    Constantine, Scott
    Lee, Elizabeth
    Dgetluck, Nancy
    White, Barbara
    [J]. ARTHRITIS & RHEUMATOLOGY, 2020, 72 (08) : 1350 - 1360
  • [8] SAFETY AND EFFICACY OF SUBCUTANEOUS TOCILIZUMAB IN SYSTEMIC SCLEROSIS: RESULTS FROM THE OPEN-LABEL PERIOD OF THE PHASE 3 FOCUSSCED TRIAL
    Khanna, D.
    Lin, C. J. F.
    Spotswood, H.
    Siegel, J.
    Furst, D.
    Denton, C.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 390 - 390
  • [9] Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial (vol 387, pg 2630, 2016)
    Khanna, D.
    Denton, C. P.
    Jahreis, Angelika A.
    [J]. LANCET, 2018, 391 (10128): : 1356 - 1356
  • [10] Efficacy and Safety of Tocilizumab for the Treatment of Systemic Sclerosis: Results from a Phase 3 Randomized Controlled Trial
    Khanna, Dinesh
    Lin, Celia J. F.
    Kuwana, Masataka
    Allanore, Yannick
    Batalov, Anastas
    Butrimiene, Irena
    Carreira, Patricia
    Cerinic, Marco Matucci
    Distler, Oliver
    Kaliterna, Dusanka Martinovic
    Mihai, Carina
    Mogensen, Mette
    Olesinska, Marzena
    Pope, Janet E.
    Riemekasten, Gabriela
    Rodriguez-Reyna, Tatiana S.
    Jose Santos, Maria
    van Laar, Jacob
    Spotswood, Helen
    Siegel, Jeffrey
    Jahreis, Angelika
    Furst, Daniel E.
    Denton, Christopher P.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70
12345